Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your medical record nudge you toward cancer gene testing?

NCT ID NCT07876349

Diagnosis Sponsor: Columbia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 15, 2026 · Last updated Oct 16, 2026 · Updated 1 time

Summary

Researchers at Columbia University are testing whether tools built into the electronic health record can increase genetic testing for hereditary breast and ovarian cancer among women with a family history of the disease. The study enrolls women aged 21 to 75 who have no personal history of breast or ovarian cancer and no prior genetic testing, but who screen positive on a family history questionnaire. Primary care providers receive alerts, and patients get referral information and access to a decision aid website called RealRisks. The trial measures changes in patients' knowledge about genetic testing and their beliefs about cancer risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
electronic health record alerts, family history screening, and a patient decision aid website
What this could lead to
If the approach works, clinics could use routine electronic health record tools to find more women at risk for hereditary breast and ovarian cancer and connect them with genetic counseling and testing.
What could go wrong
This is a small pilot study in a few primary care clinics, so the results may not apply to other settings. Alerts and websites often fail to change busy clinicians' behavior, and patients may not follow through on testing referrals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 55 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women, age 21-75 years * Completed Six-Point Scale (SPS) family history screener with a score of 6 or higher. * Seen in NewYork Presbyterian primary care clinic selected for pilot testing * No personal history of breast or ovarian cancer * No prior germline HBOC genetic testing * English or Spanish-speaking * Access to a smartphone, tablet, or computer * Able to provide written, verbal, or online informed consent Exclusion criteria: \- Patients who previously participated in the development studies for RealRisks and BNAV.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hereditary breast ovarian cancer syndrome hereditary neoplastic syndrome ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Hereditary cancer syndrome Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.